Ustekinumab, as a novel biologic, is the world’s first biologic targeting the interleukin pathway, and is a fully human monoclonal antibody produced using transgenic technology. It is currently the first-line drug for the treatment of Crohn’s disease, and is used effectively in clinical practice. Compared with other drugs, ursinumab has better efficacy and higher safety. The advantages of ustekinumab also lie in higher effectiveness, convenient injection and drug economy after price reduction. More importantly, ustekinumab produces anti-drug antibodies at a lower rate, thus reducing the risk of patients needing to change their medication due to adverse reactions and enabling long-term maintenance of efficacy. Note that it is contraindicated in persons with hypersensitivity reactions to the active ingredient or any excipients in the drug, and is contraindicated in persons with clinically significant active infections such as active tuberculosis. There is no generalized cure for Crohn’s disease, and many patients require surgical treatment when complications such as intestinal obstruction or gastrointestinal perforation occur. The recurrence rate of the disease is related to the extent of the lesion, the strength of the disease attack, the prolongation of the course of the disease, and the increase in age. It is recommended that Crohn’s patients should choose the appropriate treatment plan under the guidance of their doctors, taking into account the characteristics of their own conditions, and should not abuse drugs.